Scarica l'app Stockscreener
461.85
0.29%
-1.05
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché VRTX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$462.90
Aprire:
$463
Volume 24 ore:
28,307
Relative Volume:
0.02
Capitalizzazione di mercato:
$117.10B
Reddito:
$11.74B
Utile/perdita netta:
$3.68B
Rapporto P/E:
32.55
EPS:
14.1888
Flusso di cassa netto:
$3.34B
1 W Prestazione:
+0.27%
1M Prestazione:
+6.44%
6M Prestazione:
+4.59%
1 anno Prestazione:
+12.91%
Intervallo 1D:
$461.37
$463.55
Intervallo di 1 settimana:
$457.04
$464.44
Portata 52W:
$362.50
$519.68
Vertex Pharmaceuticals Inc Stock (VRTX) Company Profile
Nome
Vertex Pharmaceuticals Inc
Settore
Industria
Telefono
(617) 341-6393
Indirizzo
50 NORTHERN AVENUE, BOSTON, MA
Confronta VRTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VRTX
Vertex Pharmaceuticals Inc
|
461.54 | 117.45B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
782.81 | 82.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.74 | 52.92B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
842.25 | 52.02B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.17 | 37.94B | 447.02M | -1.18B | -906.14M | -6.1812 |
Vertex Pharmaceuticals Inc Stock (VRTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-03 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-25 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2025-09-03 | Iniziato | Raymond James | Mkt Perform |
| 2025-08-06 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2025-05-07 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2025-05-06 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-02-12 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-02-11 | Aggiornamento | Canaccord Genuity | Sell → Hold |
| 2025-01-30 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-12-20 | Reiterato | H.C. Wainwright | Buy |
| 2024-12-19 | Downgrade | Oppenheimer | Outperform → Perform |
| 2024-12-09 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-10-16 | Iniziato | Scotiabank | Sector Perform |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-05 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-06-27 | Iniziato | Redburn Atlantic | Buy |
| 2024-04-11 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2024-02-15 | Iniziato | Wolfe Research | Outperform |
| 2024-02-06 | Downgrade | Evercore ISI | Outperform → In-line |
| 2024-02-02 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2024-01-31 | Downgrade | Maxim Group | Buy → Hold |
| 2024-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2024-01-24 | Downgrade | Canaccord Genuity | Hold → Sell |
| 2023-12-14 | Reiterato | RBC Capital Mkts | Sector Perform |
| 2023-05-30 | Iniziato | William Blair | Outperform |
| 2023-05-04 | Ripresa | Piper Sandler | Overweight |
| 2023-03-21 | Iniziato | Bernstein | Outperform |
| 2023-01-18 | Iniziato | Canaccord Genuity | Hold |
| 2023-01-17 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2022-12-19 | Downgrade | Jefferies | Buy → Hold |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-06-01 | Aggiornamento | Maxim Group | Hold → Buy |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-05-06 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-05-03 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2022-02-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-01-27 | Reiterato | JP Morgan | Overweight |
| 2022-01-27 | Reiterato | Morgan Stanley | Underweight |
| 2022-01-27 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-01-27 | Reiterato | Stifel | Hold |
| 2022-01-27 | Reiterato | Wolfe Research | Outperform |
| 2022-01-20 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-12-09 | Iniziato | Wells Fargo | Overweight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-11-19 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2021-09-09 | Downgrade | Stifel | Buy → Hold |
| 2021-09-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2021-07-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| 2021-07-19 | Ripresa | Wolfe Research | Outperform |
| 2021-07-01 | Iniziato | Raymond James | Mkt Perform |
| 2021-06-11 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-02-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2021-02-02 | Reiterato | H.C. Wainwright | Buy |
| 2020-12-30 | Iniziato | Daiwa Securities | Outperform |
| 2020-11-30 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2020-11-20 | Iniziato | Bernstein | Outperform |
| 2020-10-28 | Iniziato | UBS | Buy |
| 2020-07-31 | Reiterato | H.C. Wainwright | Buy |
| 2020-07-08 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-04-30 | Reiterato | H.C. Wainwright | Buy |
| 2020-04-28 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2020-03-04 | Iniziato | Barclays | Overweight |
| 2020-01-31 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2019-11-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-09-03 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-08-01 | Downgrade | Needham | Buy → Hold |
| 2019-05-23 | Ripresa | Citigroup | Buy |
| 2019-05-21 | Iniziato | Credit Suisse | Outperform |
| 2019-04-12 | Iniziato | Evercore ISI | In-line |
| 2019-03-26 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2019-03-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2019-02-06 | Downgrade | Maxim Group | Buy → Hold |
Mostra tutto
Vertex Pharmaceuticals Inc Borsa (VRTX) Ultime notizie
Should You Be Confident in Vertex Pharmaceuticals Incorporated’s (VRTX) Long-Term Outlook? - Insider Monkey
Vertex Pharma’s Cystic Fibrosis Franchise: How Trikafta Powers the Pipeline — and the Stock - AD HOC NEWS
3 Supercharged Growth Stocks to Buy and Hold Into the 2030s - The Motley Fool
Biotech Stocks To Keep An Eye OnDecember 25th - MarketBeat
Vertex Pharma stock: Biotech momentum meets Wall Street optimism - AD HOC NEWS
Forget Moderna Stock, This is a Much Better Buy - Yahoo Finance
Vertex Pharmaceuticals Earnings Notes - Trefis
Greenwood Capital Associates LLC Acquires 2,514 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Pacer Advisors Inc. Acquires 26,543 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Market Review: How analysts rate Vertex Pharmaceuticals Incorporated stock todayJuly 2025 Fed Impact & Long-Term Safe Investment Plans - moha.gov.vn
Vertex Pharmaceuticals Incorporated $VRTX Shares Bought by Vontobel Holding Ltd. - MarketBeat
GLOBALT Investments LLC GA Has $1.87 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Leerink Partners Adjusts Price Target on Vertex Pharmaceuticals to $525 From $456 - marketscreener.com
Is CRISPR Therapeutics Stock Yesterday's News? - Finviz
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by DAVENPORT & Co LLC - MarketBeat
Andrew Hill Investment Advisors Inc. Sells 4,294 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Anderson Hoagland & Co. - MarketBeat
Vertex Pharmaceuticals Incorporated (VRTX) is a trending stock: Facts to know before betting on it - MSN
Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Vertex to Present at the 44th Annual J.P. Morgan Healthcare Conference on January 12 - BioSpace
Vertex Pharmaceuticals (VRTX): Valuation Check After Positive CASGEVY Pediatric Data and Kidney Disease Breakthrough Progress - Yahoo Finance
Vertex Pharmaceuticals: Strong Journavx Launch and Durable CF Franchise Underpin Buy Rating and Long-Term Growth Upside - TipRanks
Vertex Pharmaceuticals (VRTX) Stock Week Ahead: Holiday-Shortened Trading, New Gene-Therapy Data, and Fresh Analyst Targets (Dec. 22–26, 2025) - ts2.tech
Best Biotech Stocks To Watch TodayDecember 21st - MarketBeat
Best Biotech Stocks To Watch NowDecember 16th - MarketBeat
Foster Victor Wealth Advisors LLC Has $13.66 Million Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Flputnam Investment Management Co. Sells 3,065 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Congress Asset Management Co. Cuts Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock News, Forecasts and Analyst Outlook on Dec. 20, 2025: Casgevy Pediatric Data, Kidney Pipeline Momentum, and Journavx Launch Watch - ts2.tech
Redhawk Wealth Advisors Inc. Lowers Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
LVM Capital Management Ltd. MI Trims Stock Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals (VRTX) Stock After Hours on Dec. 19, 2025: Today’s News, Analyst Forecasts, and What to Know Before Monday’s Market Open - ts2.tech
Is Vertex Pharmaceuticals Incorporated stock ready for breakoutJuly 2025 Selloffs & Daily Entry Point Trade Alerts - Улправда
Aug Analyst Calls: Is Vertex Pharmaceuticals Incorporated stock ready for breakout2025 Price Targets & Weekly Sector Rotation Insights - ulpravda.ru
What dividend safety score for Vertex Pharmaceuticals Incorporated stockWeekly Investment Report & Weekly High Return Forecasts - Улправда
Vertex Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Voya Investment Management LLC Has $168.85 Million Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Montecito Bank & Trust Buys Shares of 2,239 Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Is Vertex Pharmaceuticals Incorporated stock attractive after correctionQuarterly Trade Summary & Daily Stock Trend Reports - Bölüm Sonu Canavarı
Is Vertex Pharmaceuticals Incorporated stock positioned well for digital economy2025 Technical Patterns & Weekly Breakout Watchlists - Улправда
Vertex Pharmaceuticals Incorporated $VRTX Shares Sold by Ipswich Investment Management Co. Inc. - MarketBeat
Thurston Springer Miller Herd & Titak Inc. Sells 2,487 Shares of Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Czech National Bank Increases Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
How analysts rate Vertex Pharmaceuticals Incorporated stock todayEarnings Miss & Reliable Intraday Trade Plans - Улправда
Vertex Pharmaceuticals Incorporated $VRTX Stake Lessened by Channel Wealth LLC - MarketBeat
Vertex Pharmaceuticals (VRTX) Registers a Bigger Fall Than the Market: Important Facts to Note - Yahoo Finance
Vertex Pharmaceuticals Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Gradient Investments LLC Boosts Position in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Corient Private Wealth LLC Cuts Stock Holdings in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Assenagon Asset Management S.A. Increases Stake in Vertex Pharmaceuticals Incorporated $VRTX - MarketBeat
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Vertex Pharmaceuticals Inc Azioni (VRTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.28%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):